# Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

> **NCT00976183** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gynecologic Oncology Associates** · enrollment: 18 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00976183
- **Lead sponsor:** Gynecologic Oncology Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** toxicities
- **Last updated:** 2017-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976183, "Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00976183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*